Fortress Biotech, Inc. (FBIO) Net margin 2016–2025
Fortress Biotech, Inc. (FBIO) net profit margin by fiscal year — reported net income divided by reported revenue.
10.8%FY2025 · since FY2016: -334.3% → 10.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 10.8% | +90.5 pp |
| FY2024 | -79.8% | -8.0 pp |
| FY2023 | -71.7% | +42.6 pp |
| FY2022 | -114.3% | -20.2 pp |
| FY2021 | -94.1% | +8.0 pp |
| FY2020 | -102.0% | +7.1 pp |
| FY2019 | -109.1% | +203.9 pp |
| FY2018 | -313.0% | +74.8 pp |
| FY2017 | -387.8% | -53.5 pp |
| FY2016 | -334.3% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More FBIO financial trends
FBIO RevenueFBIO Net incomeFBIO Gross profitFBIO Gross marginFBIO Operating incomeFBIO Operating marginFBIO Operating cash flowFBIO Free cash flowFBIO Capital expendituresFBIO Return on equityFBIO Stock buybacksFBIO Dividends paidFBIO Total assetsFBIO Total liabilitiesFBIO Shareholders’ equityFBIO overview →